Skip to content

Study · Animal study (in vivo) · mouse · 2017

2 results

Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type I.

Brockhoff M, Rion N, Chojnowska K, Wiktorowicz T, Eickhorst C, Erne B, Frank S, Angelini C, Furling D, Rüegg MA, Sinnreich M, Castets P

The Journal of clinical investigation9 Jan 2017Cited by 80 (Europe PMC)

PMID28067669 (opens in a new tab)PMCIDPMC5272183 (opens in a new tab)DOI10.1172/jci89616 (opens in a new tab)PepBankPUB-28067669
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In HSALR mice with myotonic dystrophy, AICAR strongly reduced myotonia.

    In plain wordsIn mice with myotonic dystrophy, AICAR reduced delayed muscle relaxation.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseMyotonia
    Study

    mousen: not reported in source

    HSALR myotonic dystrophy type I mice
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    AICAR, an AMPK activator, led to a strong reduction of myotonia, which was accompanied by partial correction of misregulated alternative splicing.
    1 context sentence
    Summary · context
    In a well-characterized mouse model for DM1 (HSALR mice), activation of AMPK signaling in muscle was impaired under starved conditions, while mTORC1 signaling remained active.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In HSALR mice with myotonic dystrophy, AICAR partially corrected misregulated alternative splicing.

    In plain wordsIn mice with myotonic dystrophy, AICAR partly corrected abnormal RNA splicing.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseMisregulated alternative splicing
    Study

    mousen: not reported in source

    HSALR myotonic dystrophy type I mice
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    AICAR, an AMPK activator, led to a strong reduction of myotonia, which was accompanied by partial correction of misregulated alternative splicing.
    1 context sentence
    Summary · context
    In a well-characterized mouse model for DM1 (HSALR mice), activation of AMPK signaling in muscle was impaired under starved conditions, while mTORC1 signaling remained active.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.